Aslam Hafiz M, Zhi Cassandra, Wallach Sara L
Internal Medicine, Seton Hall University, Hackensack Meridian School of Medicine, Trenton, USA.
Internal Medicine, Drexel University College of Medicine, Philadelphia, USA.
Cureus. 2019 Feb 7;11(2):e4024. doi: 10.7759/cureus.4024.
Tumor lysis syndrome (TLS) is a fatal complication of chemotherapy treatment. It is rarely seen in the treatment of solid tumors particularly in breast cancer. We presented the case of a chemo-naïve 58-year-old Caucasian woman who developed tumor lysis syndrome (TLS) after a single treatment dose of gemcitabine for metastatic breast cancer. Despite optimal management, the patient clinically deteriorates and is referred to inpatient hospice. Although targeted chemotherapy options have become increasingly effective, physicians should be aware of the rare, yet often fatal complications of TLS. Similarly, physicians should be able to quickly recognize the development of TLS to ensure swift and effective prophylaxis or treatment.
肿瘤溶解综合征（TLS）是化疗治疗的一种致命并发症。它在实体瘤治疗中很少见，尤其是在乳腺癌治疗中。我们报告了一例58岁未接受过化疗的白种女性病例，该患者在接受单剂量吉西他滨治疗转移性乳腺癌后发生了肿瘤溶解综合征（TLS）。尽管进行了最佳管理，但患者的临床状况仍恶化，并被转诊至住院临终关怀病房。尽管靶向化疗方案已变得越来越有效，但医生应意识到肿瘤溶解综合征（TLS）这种罕见但往往致命的并发症。同样，医生应能够迅速识别肿瘤溶解综合征（TLS）的发生，以确保迅速而有效地进行预防或治疗。
